Non-opioid niche Position Neumentum as a dedicated non-opioid analgesic and neurology specialty company with two lead candidates in advanced clinical stages, offering a compelling alternative to opioid therapies for pain management.

Pipeline leverage Leverage NTM-001 as a potential first-ever NSAID for continuous IV infusion and NTM-006 as an approved-in-pain-niche oral analgesic to pursue hospital, surgical, and chronic pain care markets that require opioid-sparing options.

Global partnerships Highlight existing licensing and collaboration with Nuance Pharma for Greater China to explore broader international commercialization, suggesting a path to accelerate global market entry and distribution.

Early-stage traction Capitalize on the company’s growth narrative and recent clinical progress to engage health systems, payers, and KOLs for early access programs, research collaborations, and strategic funding to support late-stage development.

Finite offerings Target niche pain indications and neurology indications where non-opioid options are scarce, emphasizing differentiated safety profiles and abuse-deterrence as key selling points to drive formulary inclusion and clinician adoption.